NLRP3 and Parkinson disease: Inhibition of microglial activation by MCC950, a small molecule that inhibits inflammasomes by blocking the activation of NLR family pyrin domain containing 3 (NLRP3), or by NLY01, a glucagon-like peptide-1 receptor agonist that inhibits microglial activation, decreases PFF-induced α-syn pathology and DA neuronal loss as well as motor behavior deficits in a PFF mouse model in which a single striatal injection of synthetic α-syn fibrils drives the transmission of pathological misfolded α-syn in WT mice [60, 61], which suggests a link between microglial activation and α-syn pathology in PD.